Evan Wang
Stock Analyst at Guggenheim
(0.22)
# 4,344
Out of 5,065 analysts
7
Total ratings
25%
Success rate
-17.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Reiterates: Neutral | n/a | $105.00 | - | 3 | Dec 12, 2024 | |
| CVAC CureVac | Reiterates: Neutral | n/a | $5.03 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $2.50 | +260.00% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $8.69 | +95.63% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $23.72 | - | 1 | Apr 26, 2023 |
Spruce Biosciences
Dec 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $105.00
Upside: -
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $5.03
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $2.50
Upside: +260.00%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $8.69
Upside: +95.63%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $23.72
Upside: -